Original-Research

Clinuvel Pharmaceuticals Ltd (von Sphene Capital GmbH): Buy

^

Original-Research: Clinuvel Pharmaceuticals Ltd - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Clinuvel Pharmaceuticals Ltd

Unternehmen: Clinuvel Pharmaceuticals Ltd
ISIN: AU000000CUV3

Anlass der Studie: Initiation of Coverage
Empfehlung: Buy
seit: 30.01.2018
Kursziel: AUD 31,70
Kursziel auf Sicht von: 12 Monate
Letzte Ratingänderung: -
Analyst: Peter Hasler

The light protection enabler

We're initiating coverage of Australian Clinuvel with a buy rating and a price target of AUD 31.70 per share, since we believe investors are not fully factoring in potential opportunities to Clinuvel's long-term growth in the global skin protection market. The orphan disease drug company is dramatically expanding top-line growth in the near-term as we expect the company to expand its global footprint in EPP. Apart from these significant growth opportunities, that even a rare disease like EPP offers, we expect even more in the years to come, since (1) Clinuvel is expected to launch its vitiligo product in 2021e, representing a substantial larger market than the rare disease EPP, (2) the launch of a topical product should make room for the mass market of non-prescription skin care solutions, and (3) Clinuvel could also offer a treatment for various Central Nervous System disorders among them MS, dementia, Alzheimer's, Parkinson's, ALS, or Huntington's. Apart from EPP, none of these growth opportunities have so far been factored in into our company valuation, leaving substantial upside to our price target in the long-term.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/16065.pdf

Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
[phone]/ [phone]
[e-mail]

übermittelt durch die EQS Group AG.

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

°

Rating: Buy
Analyst: Sphene Capital
Kursziel: 31,70 Euro